Skip to content
    PFE
    Earnings call· Sep 2025(Q3 FY25)

    PFIZER INC PFE

    Nov 4, 2025 Source

    Executive summary

    Pfizer Q3 FY25 — Strong Non-COVID Performance and Strategic Pipeline Progress

    Pfizer delivered solid Q3 FY25 results, driven by strong performance in its non-COVID portfolio and disciplined cost management, leading to an upward revision of full-year adjusted EPS guidance. The company is actively pursuing strategic M&A and licensing deals, such as the proposed Metsera acquisition and 3SBio licensing, to enhance its long-term pipeline and growth trajectory, despite near-term dilutive impacts and ongoing legal challenges.

    Highlights

    5
    • Non-COVID products grew 4% operationally year-over-year.

    • Adjusted diluted EPS of $0.87 was ahead of expectations, benefiting from efficient operating structure and a favorable tax rate.

    • Full-year 2025 adjusted diluted EPS guidance was raised and narrowed to $3.00-$3.15 per share.

    • The Vyndaqel family achieved 7% year-over-year global operational growth.

    • Nurtec achieved 22% year-over-year global operational growth.

    Concerns

    5
    • Total revenues decreased 7% operationally year-over-year, primarily due to a decline in COVID products (Paxlovid, Comirnaty).

    • Paxlovid experienced reduced demand from lower disease incidence and prior year's onetime government stockpiling.

    • The proposed Metsera acquisition is expected to be approximately $0.16 dilutive to 2026 adjusted EPS.

    • The 3SBio deal is expected to be approximately $0.05 dilutive to 2026 adjusted EPS.

    • Gross leverage is expected to be above the 2.7x target upon the close of the Metsera transaction.

    Guidance & targets

    13
    CategoryTargetConfidence
    Full-year 2025 Revenue
    $61 billion to $64 billion
    high materiality
    High
    Full-year 2025 Adjusted R&D
    $10 billion to $11 billion
    medium materiality
    High
    Full-year 2025 Effective Tax Rate
    approximately 11%
    medium materiality
    High
    Full-year 2025 Adjusted Diluted EPS
    $3.00 to $3.15
    high materiality
    High
    Metsera Acquisition Dilution
    approximately $0.16 dilutive
    high materiality
    High
    3SBio Deal Dilution
    approximately $0.05 dilutive
    medium materiality
    High
    Manufacturing Optimization Program Savings
    $1.5 billion
    medium materiality
    High
    Cost Realignment Program Savings
    at least $4.5 billion
    medium materiality
    High
    Total Cost Savings (Manufacturing Optimization + Cost Realignment)
    approximately $7.7 billion
    high materiality
    High
    R&D Savings Reinvestment
    $500 million
    medium materiality
    High
    Adult 25-valent PCV Program Phase III Start
    next year
    medium materiality
    Medium
    Pediatric 25-valent PCV Program Phase III Start
    2026
    medium materiality
    Medium
    2026 Guidance Release
    by the end of this year
    low materiality
    High

    Segment performance

    10
    SegmentRevenueYoYQoQMargin
    Non-COVID Products
    Solid performance across the portfolio.
    4% operational
    COVID Products
    Decline primarily due to Paxlovid, and to a lesser extent Comirnaty, driven by reduced demand from lower disease incidence and prior year's onetime stockpiling.
    decline
    Recently Launched and Acquired Products
    Revenue for the first 9 months of 2025. Lower growth rate in Q3 compared to Q2 due to timing of pediatric CDC shipments of Prevnar and a onetime favorable impact in Q2 for Seagen products transitioning to wholesale distribution.
    $7.3 billion9% operational
    Vyndaqel Family
    Strong demand reinforced its foundation as treatment for ATTR cardiomyopathy. Volume growth offset by IRA manufacturer rebates and payer contracting gross-to-net headwinds.
    Total patients on treatment internationally: 40% growthU.S. demand growth: double-digitMarket leadership: continued strongAccess: 90% in U.S.
    7% operational
    Nurtec
    New consumer campaigns performing well and effective sharing of clinical data with healthcare professionals.
    Primary care penetration in U.S.: leads oral CGRP classInternational uptake: strong
    22% operational
    Padcev
    Padcev in combination with pembrolizumab continues to expand utilization and is established as a standard of care first-line treatment for locally advanced metastatic urothelial cancer. Q3 performance impacted by Q2 wholesaler transition for Seagen products.
    Share among cisplatin-ineligible a/mUC patients: 55%Share among cisplatin-eligible a/mUC patients: 45% to 50%
    13% operational
    Prevnar Family (International)
    Strong performance driven by launches in several key markets.
    Pediatric pneumococcal vaccination leader: YesPublic funding secured: ~140 national immunization programsAdult pneumococcal conjugate vaccines: established leader among
    17% operational
    Prevnar (U.S.)
    Experienced a year-over-year decline due to delayed timing of government bulk order in the pediatric market (60% of U.S. Prevnar revenues).
    Market-leading position for adults: YesExpanded recommendation for adults over 50: grew with
    decline
    Abrysvo (International)
    Significant momentum due to expanded access in key markets.
    75% operational
    Abrysvo (U.S.)
    Experiencing a headwind of a more difficult-to-activate population in its third RSV season.
    Market share in shipped-dose volume: 59%

    Operational metrics

    19
    Adjusted Gross Margin
    76%
    Q3 FY25

    Generally remained in the mid- to upper 70s over the past 2 years, excluding Comirnaty.

    Adjusted Operating Expense
    $7 billion+21% operationally YoY
    Q3 FY25

    Excluding the 3SBio deal, adjusted operating expenses contracted by approximately $150 million versus last year.

    Acquired In-Process R&D Expenses
    $1.4 billionincreased
    Q3 FY25

    Largely resulting from the 3SBio deal.

    Gross Leverage
    2.7x
    end of Q3 FY25

    Expected to be above 2.7x target upon close of Metsera transaction, with plans to bring it back down over time.

    Dividend Returned to Shareholders
    $7.3 billion
    first 9 months of '25

    Via quarterly dividend.

    Internal R&D Investment
    $7.2 billion
    first 9 months of '25

    Investment in internal R&D.

    Business Development Transactions Investment
    $1.6 billion
    first 9 months of '25

    Investment in business development transactions.

    BD Capacity
    $13 billion
    Q3 FY25

    Remaining business development capacity.

    Metsera Acquisition Dilution
    $0.16dilutive
    2026

    Expected dilution to adjusted EPS.

    3SBio Deal Dilution
    $0.05dilutive
    2026

    Expected dilution to adjusted EPS.

    Manufacturing Optimization Program Savings
    $1.5 billion
    by end of '27

    Expected savings to support long-term operating margin expansion.

    Cost Realignment Program Savings
    $4.5 billioncumulative net
    by end of '25

    Goal for cumulative net cost savings.

    Total Cost Savings
    $7.7 billion
    by end of '27

    Total expected savings from both programs.

    R&D Savings Reinvestment
    $500 million
    by end of 2026

    Identified R&D savings to be reinvested in the pipeline.

    Braftovi and Mektovi New Patient Starts
    30 percentage pointsincrease
    since Oct '23 launch

    Continued strong year-over-year growth.

    Lung Cancer Market Size
    $70 billion
    by year 2030

    Expected market size.

    U.S. Addressable Population for Muscle Invasive Bladder Cancer
    22,500
    potential additional

    Potential increase if Padcev + pembrolizumab is approved for this indication, beyond current ~18,000 patients in metastatic urothelial cancer.

    U.S. Patient Population for Non-Metastatic Hormone-Sensitive Prostate Cancer with High-Risk Biochemical Recurrence
    16,000
    approximate

    Rapid uptake of XTANDI in this population.

    Serotype 3 Contribution to Invasive Pneumococcal Disease
    20%
    current

    Estimated cause of invasive disease.

    Industry KPIs

    8
    MetricValueDetails
    EPS revenue guidance$61B to $64BUSD
    Pricing policy impactdilutive impact
    Pipeline clinical milestones3trials
    Regulatory approvals filingsFDA concluded Pfizer may resume enrollment
    Therapeutic drug market share55%%
    Geographic regional revenue growth40%%
    Clinical trial efficacy safety datareduced risk of recurrence and death by at least half
    Business development capacity deal appetite$13BUSD

    Deals & partnerships

    2
    MetseraProposed acquisition of a company with a pipeline in obesity.approximately $4.9 billion

    Additional contingent value rights tied to successful pipeline progression. U.S. Federal Trade Commission granted early termination of the HSR waiting period. Pfizer has taken legal action to enforce and preserve its rights under the merger agreement against Novo Nordisk's competing offer.

    3SBioLicensing agreement for SSGJ-707 (PD-1 VEGF bispecific).$1.35 billion

    Upfront payment. Strategically enhanced Pfizer's pipeline with a foundational asset for oncology.

    Risks & headwinds

    7
    Decline in COVID product demandQ3 FY25, ongoing

    Revenues decreased 7% operationally year-over-year, primarily due to Paxlovid reduced demand from lower disease incidence and prior year's onetime government stockpiling.

    Mitigation: Full-year EPS guidance substantially derisked against lower-than-anticipated COVID trends.

    Delayed timing of government bulk order for Prevnar in the U.S.Q3 FY25

    Year-over-year decline in the quarter for U.S. Prevnar.

    Mitigation: Described as 'a question of time,' implying temporary impact.

    Difficult-to-activate population for Abrysvo in the U.S.Third RSV season

    Headwind in the U.S. market.

    Mitigation: Strengthening position with 59% market share in U.S. shipped-dose volume.

    Dilutive impact from Metsera and 3SBio deals2026 and dilutive through 2030 for Metsera

    Metsera acquisition expected to be approximately $0.16 dilutive to 2026 adjusted EPS; 3SBio deal expected to be approximately $0.05 dilutive to 2026 adjusted EPS.

    Mitigation: Expected to set up strong potential revenue growth trajectory in 2030 and beyond.

    Increased gross leverage post-Metsera acquisitionPost-Metsera close

    Gross leverage expected to be above 2.7x target.

    Mitigation: Expect to bring leverage back down to target levels over time.

    Legal challenges and antitrust concerns regarding Metsera acquisitionOngoing

    Novo Nordisk's offer described as 'illusory' and violating antitrust law, with a high risk of non-consummation due to antitrust concerns.

    Mitigation: Pfizer pursuing all legal resources; FTC granted early termination of HSR waiting period for Pfizer's deal.

    Impact of U.S. government agreement on drug pricing2026

    Expected dilutive impact to 2026 financial outlook.

    Mitigation: Agreement provides clarity for business and investments; hoping for changes in international pricing approaches to address unsustainable price differentials.

    What to watch in Q4 FY25

    5

    Metsera acquisition status

    Next quarter (Q4 FY25 / early 2026)
    CurrentProposed, HSR cleared, pending shareholder vote Nov 13
    TargetClosed

    Why it matters

    Critical for Pfizer's long-term growth strategy in obesity and near-term EPS dilution.

    We are encouraged by the U.S. Federal Trade Commission's decision to grant early termination of the HSR waiting period, which is unprecedented🌐 during a government shutdown and clears the path to completing this transaction following the Metsera shareholder vote on November 13.

    Q&A highlights

    7

    Comment on Vyndamax pricing and market share dynamics given new competition, and how the muscle-invasive bladder cancer indication will impact Padcev uptake.

    Vyndamax demand is strong, but net sales were impacted by IRA rebates and payer contracting, performing as expected. Padcev's Q3 performance was affected by a Q2 wholesaler transition, with growth expected to resume in Q4. The MIBC indication will open up an additional ~22,000 patients.

    Vyndamax is performing exactly where we thought it would and consistent with what we guided and performance continues to reflect strong diagnosis, broad access, improving affordability dynamics, and that's going to continue to grow our volume.

    asked by Vamil Divan · answered by Aamir Malik

    3 min read6 chapters

    Detailed Narrative

    01

    Metsera Acquisition & Legal Battle

    Pfizer is actively pursuing the acquisition of Metsera for approximately $4.9 billion, with additional contingent value rights. The company views Novo Nordisk's competing offer as 'illusory' and potentially anti-competitive, citing a high risk of non-consummation due to antitrust concerns. Pfizer received early termination of the HSR waiting period from the FTC, which it sees as clearing the path for its transaction. The company remains confident in the value creation potential in the high-growth obesity therapeutic area, leveraging its scientific and commercial strengths.

    02

    Strategic Pipeline Enhancements

    Pfizer has strategically enhanced its pipeline through a licensing agreement with 3SBio for SSGJ-707, a PD-1 VEGF bispecific. Encouraging Phase II efficacy and safety data for 707 in first-line metastatic colorectal cancer were presented at ESMO, with further clinical data expected at the upcoming SITC meeting. The company plans a robust clinical development program for 707, leveraging its deep experience in multi-specific antibody therapeutics and ability to develop unique combination regimens.

    03

    Oncology Portfolio Momentum

    The oncology portfolio demonstrated strong progress with new Phase III data for Padcev in combination with pembrolizumab, showing reduced recurrence and death risk by at least half for cisplatin-ineligible muscle-invasive cancer patients. This data could expand the U.S. addressable population by approximately 22,500 patients. Braftovi and Mektovi presented follow-up results from the PHAROS trial, showing a substantial median overall survival benefit of 47.6 months in treatment-naive metastatic non-small cell lung cancer with a BRAF V600E mutation, reinforcing Pfizer's lung cancer strategy. XTANDI also demonstrated overall survival benefit in non-metastatic hormone-sensitive prostate cancer.

    04

    Vaccines Portfolio Development

    Pfizer is committed to maintaining leadership in the pneumococcal conjugate vaccine (PCV) space. While the U.S. Prevnar market experienced a year-over-year decline due to delayed government bulk orders, the international market grew 17% operationally. The company plans to start Phase III studies for its adult and pediatric 25-valent PCV programs in 2026, aiming for a single vaccine across age groups with potential for improved immunogenicity against serotype 3, which causes approximately 20% of invasive disease in the 65-plus population in the U.S. and EU.

    05

    Cost Management & Capital Allocation

    Pfizer is executing multiple cost improvement programs, targeting $1.5 billion in savings from manufacturing optimization by the end of 2027 and at least $4.5 billion in cumulative net cost savings from its cost realignment program by the end of 2025. Total expected savings are approximately $7.7 billion by the end of 2027, with $500 million from R&D reinvested into the pipeline. In the first nine months of 2025, the company returned $7.3 billion to shareholders via dividends and invested $7.2 billion in internal R&D, alongside $1.6 billion in business development transactions.

    06

    U.S. Government Agreement and International Pricing

    Pfizer reached a new voluntary agreement with the U.S. government to help ensure lower prescription drug prices for U.S. patients and align prices with other developed countries. This agreement also provides a 3-year grace period from certain U.S. tariffs in exchange for investment in U.S. manufacturing. While it has no impact on 2025 guidance, a dilutive impact is expected in 2026. The company hopes this agreement will encourage international markets to adjust their pricing approaches, as the current price differential is deemed unsustainable.

    AI-generated summary of the company’s earnings call. Not investment advice.